King Pharma's pain drug Embeda receives US FA approval

King Pharmaceuticals, Inc announced that the US Food and Drug Administration (FDA) has approved Embeda (morphine sulfate and naltrexone hydrochloride) extended release capsules for oral use, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Embeda is the first FDA-approved long-acting opioid that is designed to reduce drug liking and euphoria when tampered with by crushing or chewing.